Ashibio Takes Shelved Gilead Drug In New Direction

On the back of a “truly one in a million” case, Ashibio has revived research into Gilead's discontinued asset andecaliximab after it showed promise in the ultra-rare musculoskeletal condition FOP.

Andecaliximab gets new lease of life • Source: Shutterstock

Ashibio says that its recent $40m funding round will facilitate its R&D efforts in bone and connective tissue disorders, with a specific focus on fibrodysplasia ossificans progressiva (FOP), as it advances andecaliximab, a discontinued asset licensed from Gilead Sciences, Inc..

The company, founded in 2022, has come out of stealth with a seed and series A financing led by MPM...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip